Loading
A phase 3 trial of toripalimab in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.
Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) is a phase 3, randomised interventional study registered as NCT04772287 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 341 participants, started 2021-03-31 and due to reach its primary completion in 2026-12-30. Interventions recorded: Toripalimab; Toripalimab mimetic (placebo). Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Disease-free survival (DFS). Lung eligibility wording from the registry: "Histological diagnosis of primary non-small cell lung cancer (NSCLC)". No results are recorded here; the registry entry is the source.
Shares ALK-positive non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Toripalimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Toripalimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares ALK-positive non-small-cell lung cancer, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.